Better retention of Malaysian opiate dependents treated with high dose methadone in methadone maintenance therapy

Harm Reduction Journal

Volumn 7, Issue , 2010, Pages

  Mohamad, Nasir ^a,b   Bakar, Nor H A ^a   Musa, Nurfadhlina ^a   Talib, Nazila ^a   Ismail, Rusli ^a  

^a INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

^b SCHOOL OF MEDICAL SCIENCES   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE;

ADULT; ARTICLE; BEHAVIORAL SCIENCE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG USE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALAYSIA; MALE; OPIATE ADDICTION; PATIENT MONITORING; SENSITIVITY AND SPECIFICITY;

EID: 78650099648     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/1477-7517-7-30     Document Type: Article

References (44)

1. Joseph H, Stancliff S, Langrod J. Methadone Maintenance Treatment (MMT): a review of historical and clinical issue. Mt Sinai J Med 2000, 67:347-364.
2. AIDS in Malaysia. , http://www.ptfmalaysia.org/images/HIV-AIDS-1986-2007-Statistics.pdf
3. Payte JT. A brief history of methadone in the treatment of opioid dependence: a personal prespective. J Psychoactive Drugs 1991, 23:103-107.
4. Rettig RA, Yarmolonsky A. Federal Regulation of Methadone Treatment 1995, Washington DC: National Academy Press.
5. National Instittutes of Health Effective Medical Treatment of Opiate Addiction 1997, Bethesda MD: National Instittutes of Health, National Instittutes of Health.
6. Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA 1988, 260:3025-3029. 10.1001/jama.260.20.3025, 2846900.
7. Joseph H, Appel P. Historical prespectives and public health issues. State Methadone Treatment Guidelines Treatment Improvement Protocol (TIP) 1993, 1:11-24. Rockville MD: U.S. Department of Health and Human Services, Parrino MW.
8. Kreek MJ. A personal retrospective and prospective viewpoint. State Methadone Treatment Guidelines Treatment Improvement Protocol (TIP) 1993, 1:133-143. Rockville MD: U.S. Department of Health and Human Services, Parrino MW.
9. Payte JT, Khuri ET. Principles of methadone dose determnation. State Methadone Treatment Guidelins 1993, 1:47-58. Rockville MD: Department of Health and Human Services, Parrino MW.
10. Payte JT, Zweben JE, Martin J. Opioid maintenance treatment. Principles of Addiction Medicine 2003, 751-766. Chevy Chase MD: American Society of Addiction Medicine, Graham AW.
11. Stine SM, Greenwald MK, Kosten TR. Pharmacologic therapies for opioid addiction. Principle of Addiction Medicine 2003, 735-750. Chevy Chase, MD: American Society of Addiction Medicine, Graham AW, 3.
12. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend 2000, 59:17-31. 10.1016/S0376-8716(99)00104-0, 10706972.
13. Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, DePhilippis D, Stolley P, Abrutyn E. Human Immunodeficiency Virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993, 6:1049-1056.
14. Longshore D, Hsieh S, Danila B. Methadone maintenance and needle/syringe sharing. Int J Addict 1993, 28:983-996.
15. Abbott PJ, Moore B, Delaney H, Weller S. Retrospective analyses of additional services for methadone maintenance patients. J Subst Abuse Treat 1999, 17:129-137. 10.1016/S0740-5472(98)00068-3, 10435261.
16. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, Banys P, Hall SM. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000, 283:1303-1310. 10.1001/jama.283.10.1303, 10714729.
17. Gill JS, AH S, Habil MH. The first methadone programme in Malaysia: overcoming obstacles and achieving the impossible. Asean J Psychiatry 2007, 8:64-70.
18. Gordon NB, Appel PW. Functional potential of the methadone maintained person. Alcohol Drugs and Driving 1994, 11:31-37.
19. Latowsky M. Methadone death, dosage and torsade de pointes: risk-benefit policy implications. J Psychoactive Drug 2006, 38:513-519.
20. Fanoe S, Hvidt C, Ege P, Jensen GB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart 2007, 93:1051-1055. 10.1136/hrt.2006.100180, 1955005, 17344330.
21. WHO Review and evaluation on Harm Reduction programme in Malaysia 2008, WHO commissioned reports, WHO.
22. Department of Public Health National Methadone Maintenance Therapy Guidelines 2005, Putrajaya KL: Department of Public Health, 1, Department of Public Health.
23. Cohen JS. Preventing adverse drug reactions before they occur. Medscape Pharmacotherapy 1999,
24. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005, 352:2211-2221. 10.1056/NEJMra032424, 15917386.
25. HIV/AIDS care and treatment for people who inject drugs in Asia and the Pacific: An essential practical guide. , http://www.wpro.who.int/NR/rdonlyres/C8CC1519-D40B-4AF0-92CD-1E94712FF025/0/HIVAIDSCAREANDTREATMENT_10MARCH_Web.pdf
26. Hur YM, Kaprio J, Lacono WG. Genetic influences on the difference in variability of height, weight and body mass index between Caucasian and East Asian adolescent twins. Int J Obes 2008, 32:1455-1467.
27. Liang T, Liu EW, Zhong H, Wang B, Shen LM, Wu ZL. Factors influencing the rate on retention to methadone maintenance treatment program among heroin addicts in Guizhou, China. Int J Drug policy 2009, 20:304-308. 10.1016/j.drugpo.2008.09.004, 18951777.
28. Li Y, Kantelip JP, Gerritsen-van SP, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism [Abstract]. Mol Diagn Ther 2008, 12:109-124.
29. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002, 41:1153-1193. 10.2165/00003088-200241140-00003, 12405865.
30. Eap CB, Deglon JJ, P B. Pharmacokinetics and pharmacogenetics of methadone: Clinical relevance. Heroin Add Rel Clin Probl 1999, 1:19-34.
31. Kell MJ. Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: Measurement techniques for a clinical setting. J Addict Dis 1994, 13:5-26. 10.1300/J069v13n01_02, 8018740.
32. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004, 5:895-931. 10.1517/14622416.5.7.895, 15469410.
33. Nurfadhlina M, Fazni R, Iqbal MZ, Hamid F, Ismail R. Genetic polymorphisms of CYP2B6 in Malaysian Population. Pharmacogenomic and Personalized Medicine 2009, 51.
34. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998, 46:101-110. 10.1046/j.1365-2125.1998.00764.x, 1873672, 9723817.
35. Country comparison: HIV/AIDS adult prevalence rate. , https://www.cia.gov/library/publications/the-world-factbook/rankorder/2155rank.html
36. Liu E, Liang T, Shen L, Zhong H, Wang B, Wu Z, Detels R. Correlates of methadone client retention: a prospective cohort study in Guizhou province, China. Int J Drug Policy 2009, 20:304-308. 10.1016/j.drugpo.2008.09.004, 2903544, 18951777.
37. Brady TM, Salvucci S, Sverdlov LS, Male A, Kyeyune H, Sikali E, DeSale S, Yu P. Methadone dosage and retention: an examination of the 60 mg/day threshold. J Addict Dis 2005, 24:23-47. 10.1300/J069v24n03_03, 16186081.
38. Mattick RP, Breen C, Kimbler J. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Syst Rev 2003,
39. Nadelman E, Mc Neely J. Doing methadone right. Pub Interest 1996, 123:83-93.
40. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate-vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999, 281:1000-1005. 10.1001/jama.281.11.1000, 10086434.
41. Managing Opioid Dependence: Treatment and Care for HIV-Positive Injecting Drug Users. , http://www.fhi.org/training/en/HIVAIDS/IDUModules/pdf/Module_04_Treatment_Care_for_HIV_positive_IDUs.pdf
42. Farré M, Mas A, Torrens M, Moreno V, CamI J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 2002, 65:283-290.
43. HIV/AIDS care and treatment for people who inject drugs in Asia and the Pacific: An essential practice guide. , http://www.wpro.who.int/NR/rdonlyers/C8CC1519-D40B-4AF0-92CD-1E94712FF025/0/HIVAIDSCAREANDTREATMENT_10MARCH_Web.pdf
44. Leavitt SB. Methadone dosing and safety in the treatment of opioid addiction. Addict Treat Forum 2003,